{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:12:56Z","timestamp":1788401576100,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128569","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T16:09:52Z","timestamp":1776269392000},"page":"128569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Safety of seasonal inactivated influenza vaccines in children 6\u00a0months\u201317\u00a0years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018\u20132023: before, during, and after the COVID-19 pandemic public health emergency"],"prefix":"10.1016","volume":"81","author":[{"given":"E. Gloria","family":"Anyalechi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary N.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally-Ann P.","family":"Johannsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Kohlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyothi","family":"Gunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly N.","family":"Works","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Romanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew B.","family":"Crist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2026.128569_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7305a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2024\u201325 influenza season","volume":"73","author":"Grohskopf","year":"2024","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.128569_bb0010","unstructured":"Committee on Infectious Diseases, American Academy of Pediatrics. Influenza. In: Kimberlin DB, R; Barnett, ED; Lynfield, R; Sawyer, MH, ed. Red book. 2024\u20132027 report of the Committee on Infectious Diseases. 33rd ed. Itasca, Illinois: American Academy of Pediatrics; 2024:511\u201322."},{"key":"10.1016\/j.vaccine.2026.128569_bb0015","unstructured":"U.S. Centers for Disease Control and Prevention. Laboratory\u2013confirmed influenza hospitalizations. US Department of Health and Human Services. Accessed July 27, 2024 (https:\/\/gis.cdc.gov\/grasp\/FluView\/FluHospRates.html)."},{"key":"10.1016\/j.vaccine.2026.128569_bb0020","article-title":"Recommendations for prevention and control of influenza in children, 2025\u20132026: policy statement","author":"Committee on Infectious Diseases, American Academy of Pediatrics","year":"2025","journal-title":"Pediatrics"},{"issue":"22","key":"10.1016\/j.vaccine.2026.128569_bb0025","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.vaccine.2016.03.048","article-title":"Post\u2013licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), july 1, 2013\u2013may 31, 2015","volume":"34","author":"Haber","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128569_bb0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1542\/peds.2004-1519","article-title":"Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the Vaccine Adverse Event Reporting System (VAERS), 1990\u20132003","volume":"115","author":"McMahon","year":"2005","journal-title":"Pediatrics"},{"issue":"32","key":"10.1016\/j.vaccine.2026.128569_bb0035","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2009.05.023","article-title":"Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6\u201323 months of age","volume":"27","author":"Rosenberg","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128569_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2022\u201323 influenza season","volume":"71","author":"Grohskopf","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"36","key":"10.1016\/j.vaccine.2026.128569_bb0045","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"issue":"19","key":"10.1016\/j.vaccine.2026.128569_bb0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.15585\/mmwr.mm6919e2","article-title":"Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration - United States, 2020","volume":"69","author":"Santoli","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128569_bb0055","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-047092","article-title":"Pediatric vaccination during the COVID-19 pandemic","volume":"148","author":"Ackerson","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128569_bb0060","unstructured":"U.S. Centers for Disease Control and Prevention and the Food and Drug Administration. VAERS- FAQs. What adverse events should healthcare providers report to VAERS after COIVD-19 vaccination? U. S. Department of Health and Human Services. Accessed June 9, 2024 (https:\/\/vaers.hhs.gov\/faq.html)."},{"key":"10.1016\/j.vaccine.2026.128569_bb0065","unstructured":"U.S. Centers for Disease Control and Prevention and the Food and Drug Administration. VAERS- Vaccine Adverse Event Reporting System. U.S. Department of Health and Human Services. Accessed June 9, 2024 (https:\/\/vaers.hhs.gov\/index.html)."},{"key":"10.1016\/j.vaccine.2026.128569_bb0070","unstructured":"Browsers | MedDRA Medical dictionary for regulatory activities. Accessed June 30, 2024. (http:\/\/www.meddra.org\/browsers)."},{"key":"10.1016\/j.vaccine.2026.128569_bb0075","unstructured":"U.S. Centers for Disease Control and Prevention and the US Food and Drug Administration. VAERS- About Us. U.S. Department of Health and Human Services. Accessed August 1, 2025 (https:\/\/vaers.hhs.gov\/about.html)."},{"issue":"11","key":"10.1016\/j.vaccine.2026.128569_bb0080","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.vaccine.2022.12.069","article-title":"Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the Vaccine Adverse Event Reporting System (VAERS) during july 1, 2021\u2013June 30, 2022","volume":"41","author":"Moro","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128569_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jpids\/piu034","article-title":"Post-licensure surveillance of trivalent live-attenuated influenza vaccine in children aged 2\u201318 years, Vaccine Adverse Event Reporting System (VAERS), United States, july 2005-June 2012","volume":"4","author":"Haber","year":"2015","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"15","key":"10.1016\/j.vaccine.2026.128569_bb0090","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2022.11.027","article-title":"Anaphylaxis: revision of the Brighton collaboration case definition","volume":"41","author":"Gold","year":"2023","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128569_bb0095","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2026.128569_bb0100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.vaccine.2003.09.008","article-title":"Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128569_bb0105","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2011.12.042","article-title":"Febrile seizures after 2010\u20132011 influenza vaccine in young children, United States: a vaccine safety signal from the Vaccine Adverse Event Reporting System (VAERS)","volume":"30","author":"Leroy","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128569_bb0110","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/cid\/civ423","article-title":"Deaths reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 1997\u20132013","volume":"61","author":"Moro","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128569_bb0115","unstructured":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Coverage by Season | FluVaxView | CDC. U.S. Department of Health & Human Services. Accessed December 10, 2024 (https:\/\/www.cdc.gov\/fluvaxview\/coverage-by-season\/index.html)."},{"key":"10.1016\/j.vaccine.2026.128569_bb0120","author":"United States Census Bureau"},{"key":"10.1016\/j.vaccine.2026.128569_bb0125","author":"United States Census Bureau"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128569_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53845","article-title":"Reports of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the United States","volume":"6","author":"Abara","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128569_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"American Statistician"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128569_bb0140","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019S spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128569_bb0150","unstructured":"Sanofi Pasteur Inc Package insert - Fluzone quadrivalent. US Food and Drug Administration. 2025. Accessed August 3, 2024. https:\/\/www.fda.gov\/media\/170019\/download?attachment."},{"key":"10.1016\/j.vaccine.2026.128569_bb0155","unstructured":"Glaxo Smith Kline Biologicals Package insert: Fluarix quadrivalent. US Food and Drug Administration. 2025. Accessed August 3, 2024. https:\/\/www.fda.gov\/media\/79278\/download?attachment."},{"key":"10.1016\/j.vaccine.2026.128569_bb0160","unstructured":"US Food and Drug Administration Vaccines licensed for use in the United States Accessed May 31, 2024. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states; 2025."},{"issue":"17","key":"10.1016\/j.vaccine.2026.128569_bb0165","first-page":"457","article-title":"Syncope after vaccination--United States, January 2005\u2013July 2007","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128569_bb0170","author":"National Center for Immunization and Respiratory Diseases - Centers for Disease Control and Prevention"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128569_bb0175","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1542\/peds.2008-0939","article-title":"Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures","volume":"121","author":"Steering Committee on Quality Improvement Management-Subcommittee on Febrile Seizures","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128569_bb0180","author":"Law"},{"key":"10.1016\/j.vaccine.2026.128569_bb0185","article-title":"Febrile seizures","volume":"351","author":"Patel","year":"2015","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128569_bb0190","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0320","article-title":"Febrile seizure risk after vaccination in children 6 to 23 months","volume":"138","author":"Duffy","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.vaccine.2026.128569_bb0195","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.vaccine.2018.07.036","article-title":"Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6\u201359\u00a0months of age: a phase 3, randomized, noninferiority study","volume":"37","author":"Statler","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128569_bb0200","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1909","article-title":"Fever after influenza, diphtheria-tetanus-acellular pertussis, and pneumococcal vaccinations","volume":"145","author":"Walter","year":"2020","journal-title":"Pediatrics"},{"issue":"8","key":"10.1016\/j.vaccine.2026.128569_bb0205","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pds.3996","article-title":"Post licensure surveillance of influenza vaccines in the vaccine safety datalink in the 2013-2014 and 2014-2015 seasons","volume":"25","author":"Li","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128569_bb0210","author":"National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128569_bb0215","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US\u2014December 14, 2020\u2013January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128569_bb0220","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, december 2020 to august 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128569_bb0225","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from december 2020 to august 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.vaccine.2026.128569_bb0230","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices - United States, june 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2026.128569_bb0235","unstructured":"Wallace M. Evidence to recommendations framework: 2023\u20132024 (Monovalent, XBB Containing) COVID-19 vaccine. ACIP Meeting. US Centers for Disease Control and Prevention;. Accessed September 12, 2023 (Slideset) (https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-09-12\/11-COVID-Wallace-508.pdf)."},{"key":"10.1016\/j.vaccine.2026.128569_bb0240","unstructured":"US Centers for Disease Control and Prevention and the Food and Drug Administration. Guide to interpreting VAERS data. US Health and Human Services. Accessed August 2, 2025 (https:\/\/vaers.hhs.gov\/data\/dataguide.html)."},{"issue":"39","key":"10.1016\/j.vaccine.2026.128569_bb0245","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1016\/j.vaccine.2012.04.005","article-title":"Algorithm to assess causality after individual adverse events following immunizations","volume":"30","author":"Halsey","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:07:09Z","timestamp":1777576029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":48,"alternative-id":["S0264410X26003774"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128569","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of seasonal inactivated influenza vaccines in children 6\u00a0months\u201317\u00a0years of age in the Vaccine Adverse Events Reporting System (VAERS) 2018\u20132023: before, during, and after the COVID-19 pandemic public health emergency","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128569"}}